更新于：2024-06-21
CJM-112
更新于：2024-06-21
概要
基本信息
在研机构- |
最高研发阶段无进展临床2期 |
首次获批日期- |
最高研发阶段(中国)无进展 |
特殊审评- |
序列信息
Sequence Code 10127842H
Sequence Code 10127849L
关联
8
项与 CJM-112 相关的临床试验Phase I/Ib, Multi-center, Open-label, Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, and identify the recommended doses of single agent CJM112, and of CJM112 or LCL161 in combination with PDR001, in patients with relapsed and/or refractory multiple myeloma.
开始日期2017-12-18 |
A randomized, subject- and investigator-blinded, placebo-controlled, multi-center, multiple dose study to assess the efficacy and safety of CJM112 in patients with inadequately controlled moderate to severe asthma
开始日期2017-12-13 |
申办/合作机构 |
A Randomized, Subject- and Investigator-blinded, Placebo Controlled, Multi-center, Multiple Dose Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Moderate to Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in development for T2-high(allergic/eosinophilic) asthma. The purpose of this study was to determine if CJM112, an anti-IL-17A antibody, displayed the clinical efficacy and safety profile to support further development in patients with inadequately controlled moderate to severe asthma with low IgE and low circulating eosinophil levels.
开始日期2017-11-06 |
100 项与 CJM-112 相关的临床结果
登录后查看更多信息
100 项与 CJM-112 相关的转化医学
登录后查看更多信息
100 项与 CJM-112 相关的专利（医药）
登录后查看更多信息
6
项与 CJM-112 相关的文献（医药）2023-12-31·The Journal of dermatological treatment
Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne
Article
作者: Rissmann, Robert ; Thiboutot, Diane M. ; Souquières, Malika ; Loesche, Christian ; Craft, Noah ; Jones, Julie ; Gatlik, Ewa
BACKGROUND:
CJM112 is a potent anti-IL-17A monoclonal antibody, whose clinical efficacy in psoriasis was recently documented. This study aimed to assess the effect of IL-17A blockade, using CJM112, in patients with moderate to severe acne.
METHODS:
A randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study was conducted on patients with moderate to severe acne. Patients received CJM112 300 mg, 75 mg, or placebo subcutaneously during Treatment Period 1 (0-12 weeks). Patients receiving placebo were re-randomized to receive CJM112 300 mg or 75 mg during Treatment Period 2 (12-24 weeks). The primary endpoint was the number of inflammatory facial lesions at Week 12.
RESULTS:
As the futility criterion was met during the interim analysis, only 52/75 (69.3%) patients were recruited. In total, 48/52 (92.3%) and 26/41 (63.4%) completed Treatment Periods 1 and 2, respectively. All groups exhibited a reduction in facial inflammatory lesions, with no difference observed between CJM112 and placebo (CJM112 300 mg 27.6 ± 20.7; CJM112 75 mg 30.4 ± 34.8; placebo 23.6 ± 13.6; primary endpoint). Additionally, no differences were observed between groups in other secondary and exploratory endpoints at Week 12.
CONCLUSIONS:
Anti-IL-17A therapy was not significantly different compared to the placebo in reducing inflammatory lesions in patients with moderate to severe acne.
2022-10-01·Experimental dermatology
Article
作者: Kolbinger, Frank ; Wieczorek, Grazyna ; Kimball, Alexa B. ; Jarvis, Philip ; Jemec, Gregor B. E. ; Prens, Errol P. ; Roth, Lukas ; Rozenberg, Izabela ; Loesche, Christian ; Bechara, Falk G. ; Weisman, Jamie ; Peters, Thomas
Abstract:
Hidradenitis Suppurativa (HS) is a chronic, recurrent, inflammatory, follicular skin disease whose pathology is complex and not fully understood. The objective of this study was to elucidate the role of IL‐17A in moderate‐to‐severe HS. Transcriptomic and histological analyses were conducted on ex vivo HS (n = 19; lesional and non‐lesional) and healthy control (n = 8) skin biopsies. Further, a Phase II exploratory, randomized, double‐blind, placebo‐controlled study was carried out in moderate‐to‐severe HS patients. Patients were treated with either CJM112 300 mg (n = 33), a fully human anti‐IL‐17A IgG1/κ monoclonal antibody, or placebo (n = 33). The main outcome of the translational analyses was to identify IL‐17A‐producing cells and indications of IL‐17A activity in HS lesional skin. The primary objective of the clinical study was to determine the efficacy of CJM112 in moderate‐to‐severe HS patients by HS‐Physician Global Assessment (HS‐PGA) responder rate at Week 16. Transcriptomic and histopathologic analyses revealed the presence of heterogeneous cell types in HS lesional skin; IL‐17A gene signatures were increased in HS lesional vs non‐lesional or healthy skin. High expression of IL‐17A was localized to T cells, neutrophils, and mast cells, confirming the transcriptional data. Clinically, the proportion of Week 16 HS‐PGA responders was significantly higher (p = 0.03) in the CJM112 group vs placebo (32.3% vs 12.5%). This study elucidated the role of the IL‐17A pathway in HS pathogenesis and clinically validated the IL‐17A pathway in moderate‐to‐severe HS patients in a proof‐of‐concept study using the anti‐IL‐17A‐specific antibody CJM112.
2021-05-01·Journal of the European Academy of Dermatology and Venereology : JEADV2区 · 医学
First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis
2区 · 医学
Article
作者: Jarvis, P. ; Kolbinger, F. ; Rozenberg, I. ; Sligh, T.S. ; Aassi, M. ; Mussmann, R. ; Kaul, M. ; Di Padova, F. ; Cebe, R. ; Rondeau, J.M. ; Espie, P. ; Calonder, C. ; Huber, T.
Abstract:
Background and objective:
Anti‐IL‐17A IgG/κ monoclonal antibody CJM112 binds both IL‐17A and IL‐17AF. The purpose of this First‐in‐Human study was to assess CJM112 effects on safety and efficacy in patients with moderate to severe plaque psoriasis.
Methods:
This study had two parts: single ascending doses of 5–450 mg subcutaneous (s.c.) CJM112 (SAD) and multi‐dose parallel groups of CJM112 15 mg, 50 mg and 150 mg s.c. low frequency or high frequency (MD). SAD/MD were double‐blind, randomized and placebo‐controlled; MD also included a secukinumab 150 mg s.c. arm as an active comparator. Patients 18–65 years with moderate to severe psoriasis were included in this study. The efficacy outcome was the change in Psoriasis Area Severity Index (PASI) from baseline to Week 4 in the SAD part of the study, and from baseline to Week 12 in the MD part.
Results:
96 patients were enrolled in this study (SAD, n = 42; MD, n = 54). In SAD, CJM112 doses from 15 mg and above demonstrated higher PASI responses compared with placebo at Week 12. CJM112 450 mg did not add further efficacy, but efficacy duration was prolonged compared with CJM112 150 mg. CJM112 MD resulted in a dose‐dependent decrease in PASI over time to Week 12. CJM112 150 mg high frequency did not exceed the effect of CJM112 150 mg low frequency and had similar efficacy to secukinumab 150 mg. The safety profile of CJM112 was as expected for an antibody targeting IL‐17A/IL‐17AF.
Conclusions:
CJM112 had clinical efficacy in moderate to severe psoriasis and was generally safe and well tolerated in the doses tested. Additional neutralization of IL‐17AF did not translate to increased clinical efficacy compared with secukinumab.
2
项与 CJM-112 相关的新闻（医药）2023-03-02
Asthma is a chronic disease that affects a substantial number of patients worldwide, including children, a number of pharmaceutical companies are involved in developing drugs for asthma. This involvement includes the development of novel therapies that being evaluated in different phases of development.
LAS VEGAS, March 2, 2023 /PRNewswire/ -- DelveInsight's
'
Asthma Pipeline Insight – 2023
' report provides comprehensive global coverage of available, marketed, and pipeline asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the asthma pipeline domain.
Key Takeaways from the Asthma Pipeline Report
DelveInsight's asthma pipeline report depicts a robust space with
90+ active players working to develop
95+ pipeline therapies for asthma treatment.
Key asthma companies such as
Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others are evaluating new asthma drugs to improve the treatment landscape.
Promising asthma pipeline therapies in various stages of development include
CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.
In
February 2023,
UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the
Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development.
Dexpramipexole is beig developed by Areteia Therapeutics to inhibit the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels.
In
February 2023, Pulmatrix, Inc. announced that the first patient dosed in a
Phase IIb trial evaluating safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma.
PUR1900 is the company's iSPERSE-enabled
dry powder formulation of itraconazole, developed for inhaled pulmonary delivery. The Phase II trial is designed as a randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and duration of treatment with itraconazole, administered as a dry powder for inhalation (PUR1900). Endpoints include safety, tolerability, and potential efficacy outcomes in adult patients with asthma and ABPA.
Olatec Therapeutics LLC in February 2023 completed the
$40 million Series A round financing, the final closing of which was led by Sanders Morris Harris ("SMH"). Participation in the round came from both existing investors as well as new investors identified by each of Sanders Morris Harris, Advection Growth Capital, and the Company.
Proceeds will be principally used to advance Olatec's lead compound,
dapansutrile, into later-stage clinical development. Dapansutrile has also been
observed to have anti-inflammatory properties and other promising activity in a broad spectrum of over
20 preclinical animal models, including arthritis,
asthma, acute myocardial infarction (AMI), heart failure, contact dermatitis, multiple sclerosis, melanoma, pancreatic and breast cancers, spinal cord injury (SCI), Parkinson's and Alzheimer's disease.
In January 2023,
Avillion LLP, announced that the
US Food and Drug Administration (FDA)
approved AstraZeneca's Airsupra (albuterol/budesonide, formerly known as PT027) for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS).
Upstream Bio, in August 2022,
initiated a Phase Ib multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient.
UPB-101 is a monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation. TSLP is a cytokine and a key driver of inflammatory response in
asthma and other allergic and inflammatory diseases.
Request a sample and discover the recent advances in asthma drug treatment @
Asthma Pipeline Report
The asthma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage asthma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the asthma clinical trial landscape.
Asthma Overview
Asthma is a chronic disease of the airways. Asthma is characterized by airway inflammation and spasm. Airways are tubes that transport air into and out of the lungs. Asthmatics cause the inside walls of the airways to become sore and swollen. Because of inflammation and tightening of the muscles surrounding the small airways, the airways in the lungs become narrow. Asthma symptoms include coughing, wheezing, shortness of breath, and chest tightness. Asthma symptoms differ from person to person. A person may have infrequent asthma attacks, have symptoms only when exercising, or have symptoms all of the time. Asthma symptoms are similar to those of many respiratory infections.
A careful clinical history is the first step in asthma diagnosis; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on quality of life.
Find out more about drugs for asthma @
New Asthma Drugs
A snapshot of the Asthma Pipeline Drugs mentioned in the report:
Learn more about the emerging asthma pipeline therapies @
Asthma Clinical Trials
Asthma Therapeutics Assessment
The
asthma pipeline report proffers an integral view of asthma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Asthma Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment
By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
Therapeutics Assessment
By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
Therapeutics Assessment
By Mechanism of Action: Immunomodulators, Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists, Interleukin 5 receptor antagonists, Matrix metalloproteinase 12 inhibitors, Aldehyde inhibitors, Bacteria replacements; Microbiome modulators, Thymic stromal lymphopoietin inhibitors; Thymic stromal lymphopoietin modulators, Interleukin-33 inhibitors, Inflammasome inhibitors; Interleukin 1 beta inhibitors; Interleukin 18 inhibitors; Interleukin inhibitors; NLRP3 protein inhibitors, Interleukin-17 inhibitors
Key Asthma Companies: Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others.
Key Asthma Pipeline Therapies: CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.
Dive deep into rich insights for new drugs for asthma treatment; visit @
Asthma Medications
Table of Contents
For further information on the asthma pipeline therapeutics, reach out @
Asthma Drug Treatment
Related Reports
Severe Asthma Market
Severe Asthma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key severe asthma companies, including
AstraZeneca, Novartis, Sanofi, among others.
Asthma Pipeline
Asthma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key asthma companies, including
GSK, AstraZeneca, Teva Pharmaceuticals, among others.
Severe Asthma Pipeline
Severe Asthma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key severe asthma companies, including
AstraZeneca, Novartis, Sanofi, among others.
Chronic Obstructive Pulmonary Disease Epidemiology Forecast
Chronic Obstructive Pulmonary Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the chronic obstructive pulmonary disease epidemiology trends.
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including
Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma, among others.
Acute Respiratory Distress Syndrome Pipeline
Acute Respiratory Distress Syndrome Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key acute respiratory distress syndrome companies, including
Bayer, Faron Pharmaceuticals, BioMarck Pharmaceuticals, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market
| Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market
Related Healthcare Blogs
Emerging Therapies for Severe Asthma Treatment
COPD Treatment Market
COPD Epidemiological Trends
Chronic Respiratory Disease Market
Promising Therapies in the ARDS Market
Rising Acute Respiratory Distress Syndrome Prevalence
ARDS Market Outlook
Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Additionally, get in touch with our business executive to explore @
Healthcare Due Diligence Services
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
临床2期上市批准临床3期临床1期
2022-08-15
药讯精选GBI NEWS第二项适应证！泽璟生物多纳非尼获批治疗晚期/转移性甲状腺癌8月15日，苏州泽璟生物制药股份有限公司发布公告称，其自主研发的1类新药甲苯磺酸多纳非尼片（商品名：泽普生，下称“多纳非尼”）用于治疗进展性、局部晚期或转移性放射性碘难治性分化型甲状腺癌适应证的新药上市申请获得批准。这是继获批用于既往未接受过全身系统性治疗的不可切除肝细胞癌后，多纳非尼获批的第二项适应证。多纳非尼是泽璟生物自主研发的口服多靶点、多激酶抑制剂类小分子抗肿瘤药物，本次获批主要是基于多纳非尼治疗局部晚期/转移性放射性碘难治性分化型甲状腺癌的多中心、随机、双盲、安慰剂对照的III期临床试验结果。GBI数据库显示，泽璟制药已在国内针对多纳非尼启动了83项临床，其中3期临床共8项，适应证包括晚期肝细胞癌、分化型甲状腺癌、晚期结直肠癌等，其中结直肠癌适应证因III期临床失败而终止开发。**戳文末“阅读原文”定制/订阅医疗行业新闻资讯三生国健IL-17A单抗治疗银屑病II期临试达主要终点三生国健宣布，其自主研发的抗IL-17A人源化单克隆抗体药物（研发代号：SSGJ-608），在中重度斑块状银屑病患者中开展的一项随机、双盲、安慰剂对照、多剂量递增及剂量探索的II期临床研究达到主要终点。SSGJ-608产品是三生国健自主研发设计、筛选并人源化的抗IL-17A单克隆抗体，具有全新的氨基酸序列。目前全球已有3个IL-17A抗体药物获批上市，包括诺华可善挺（司库奇尤单抗）、礼来的拓咨（依奇珠单抗），以及Biocad的Netakimab（Efleira）。处于研发阶段的IL-17A抑制剂还有优时比Bimekizumab（IL-17A/F）、诺华CJM112、强生/方坦思CNTO6785、智翔金泰GR1501、江苏荃信QX002N、君实生物JS005、华海药业HB0017等。经查询，2020年司库奇尤单抗、 依奇珠单抗、Netakimab的全球销售额合计约57.87亿美元。**戳文末“阅读原文”定制/订阅医疗行业新闻资讯企业动态GBI NEWS毕诺济生物完成过亿元天使+轮融资，加速细胞治疗研发转化8月15日，毕诺济生物（Bennu Biotherapeutics）宣布完成逾亿人民币的天使+轮融资。本轮融资由渶策资本领投，生命园创投及智诚资本等知名基金共同参与完成，筹集的资金将主要用于在全球范围内推进产品管线的临床前研究及临床开发。毕诺济生物成立于2021年11月，由董晨院士联合高瓴创投、辰德资本等机构共同创立，成立至今已累计融资数亿人民币。毕诺济生物深耕T细胞创新疗法领域，已搭建独有的T细胞命运调控靶点开发平台和T细胞工程化改造平台。公司致力于开发基于多种T细胞类型的下一代细胞疗法，以解决现有疗法的诸多问题，为该领域带来革命性创新。现阶段，毕诺济产品管线专注于实体瘤治疗领域，目前正在进行首个产品BEN101的生产工艺开发与药理毒理实验，并已启动临床开发相关的准备工作。**戳文末“阅读原文”定制/订阅医疗行业新闻资讯EQRx公司2022Q2财报：拟开展阿美替尼对标奥希替尼美国Ⅲ期临试美国制药公司EQRx发布2022年第二季度财报以及业务更新，包括加速在美国开发从中国合作伙伴引进的两款新药。该公司最近在美国启动了一项阿美替尼（Aumolertinib）用于一线治疗携带EGFR突变的非小细胞肺癌（NSCLC）的IIIb期桥接临床试验。值得注意的是，EQRx启动的IIIb期研究将包括评估阿美替尼与阿斯利康的泰瑞沙（奥希替尼）临床可比性的试验组，以及评估阿美替尼联合化疗一线治疗潜在临床获益试验组。此外，EQRx正与美国FDA进行讨论，以在美国开展PD-L1抑制剂舒格利单抗与其它检查点抑制剂对比用于治疗IV期NSCLC的一项随机对照临床试验，目的是评估GEMSTONE-302研究结果（一项在中国进行的III期研究）对当前美国医疗实践和患者群体的适用性。EQRx预计将在今年下半年在美国以外市场就舒格利单抗提交用于治疗IV期NSCLC的首个上市申请。2020年，EQRx与基石药业达成一项价值高达13亿美元的合作协议，获得舒格利单抗和PD-1抑制剂CS1003的独家授权。**戳文末“阅读原文”定制/订阅医疗行业新闻资讯近期活动新格局下，如何借助数字化平台的力量，在低成本广覆盖的同时精准触点，并利用数字化工具使学术效果可以量化评估，成为新的焦点问题。学术推广的底层思路是什么？数字化学术推广相比传统模式有何优势？药企如何推动数字化学术推广？2022年8月19日（本周五）下午4点GBI线上课堂给你答案。扫描海报二维码或点击“阅读原文”立即报名啦！点击 阅读原文 立即报名本期GBI线上课堂
财报抗体免疫疗法细胞疗法合作
100 项与 CJM-112 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 哮喘 | 临床2期 | 美国 | 2017-11-06 | |
| 哮喘 | 临床2期 | 阿根廷 | 2017-11-06 | |
| 哮喘 | 临床2期 | 比利时 | 2017-11-06 | |
| 哮喘 | 临床2期 | 丹麦 | 2017-11-06 | |
| 哮喘 | 临床2期 | 法国 | 2017-11-06 | |
| 哮喘 | 临床2期 | 德国 | 2017-11-06 | |
| 哮喘 | 临床2期 | 以色列 | 2017-11-06 | |
| 哮喘 | 临床2期 | 斯洛伐克 | 2017-11-06 | |
| 寻常痤疮 | 临床2期 | 美国 | 2016-12-22 | |
| 寻常痤疮 | 临床2期 | 德国 | 2016-12-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 118 | (CJM112 300 mg) | 繭餘壓窪鹹築遞鹹遞蓋(壓窪鑰糧簾壓醖艱廠築) = 壓蓋窪顧艱壓繭壓範簾 餘齋鹽窪繭蓋選製膚糧 (選齋夢鏇醖壓夢遞選醖, 簾餘膚鬱觸艱鑰蓋鏇齋 ~ 顧積範糧衊獵蓋壓窪鑰) 更多 | - | 2020-08-06 | ||
Placebo (Placebo) | 繭餘壓窪鹹築遞鹹遞蓋(壓窪鑰糧簾壓醖艱廠築) = 鏇鑰衊襯繭範選艱膚願 餘齋鹽窪繭蓋選製膚糧 (選齋夢鏇醖壓夢遞選醖, 簾齋艱夢願窪衊築夢膚 ~ 願鏇壓襯艱鬱餘構鏇壓) 更多 | ||||||
临床2期 | 66 | (Period 1: CJM112 High Dose) | 獵顧憲窪窪簾齋艱簾觸(遞淵簾鏇壓網顧淵鹽遞) = 獵衊顧選鑰艱獵夢繭網 製襯膚廠廠遞醖鏇憲襯 (繭鹹構簾壓鹹獵蓋鏇壓, 壓願選觸簾憲餘壓壓選 ~ 窪鏇觸窪繭簾淵網繭鑰) 更多 | - | 2019-05-23 | ||
Placebo (Period 1: Placebo) | 獵顧憲窪窪簾齋艱簾觸(遞淵簾鏇壓網顧淵鹽遞) = 選餘淵窪製憲鏇齋廠製 製襯膚廠廠遞醖鏇憲襯 (繭鹹構簾壓鹹獵蓋鏇壓, 廠製選夢齋廠獵夢積淵 ~ 淵顧鏇鹽窪蓋窪範願夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用